SCHEDULE 13G/A: Tang Capital Boosts Stake in Bolt Biotherapeutics to 8.7%

Tang Capital Management and affiliates report an 8.7% beneficial ownership stake in Bolt Biotherapeutics, Inc. following a recent reverse stock split.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively beneficially own 166,879 shares of Bolt Biotherapeutics, Inc. common stock.
• This represents an 8.7% ownership stake in the company.
• The ownership percentage is calculated based on 1,916,984 shares of Common Stock outstanding, which accounts for a one-for-twenty reverse stock split effective June 6, 2025.
• The reporting persons share both voting and dispositive power over these shares.
• This filing is an Amendment No. 3 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by a significant investor group. The maintenance of a substantial stake post-reverse split can be seen as a neutral to slightly positive signal of continued investor confidence, but it does not provide new operational or financial insights into Bolt Biotherapeutics.

Positives

• Tang Capital Management and its affiliates maintain a significant ownership stake, indicating continued conviction in Bolt Biotherapeutics.
• The filing provides clarity on the beneficial ownership structure post the one-for-twenty reverse stock split, which is a material corporate action.

Future Outlook

NA

Industry Context

This filing reflects an institutional investor's continued stake in a biotechnology company, a sector often characterized by high research and development costs and significant capital requirements. The reporting of ownership post-reverse stock split is a common procedural update in the industry, especially for companies undergoing strategic adjustments to their capital structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which could influence market perception and confidence.
• Management: Awareness of a large, active shareholder group, which may influence strategic decisions or corporate governance.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Tang Capital Management and its affiliates. While the maintenance of an 8.7% stake post-reverse stock split indicates continued investor confidence, the filing itself does not provide new fundamental information about Bolt Biotherapeutics' operational performance, financial health, or strategic direction that would warrant a 'buy' or 'sell' recommendation. It is a procedural update confirming a significant shareholder's position. Investors should 'hold' and await further operational updates or financial results from the company to make more informed decisions.

Keywords

Bolt Biotherapeutics, Tang Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Reverse Stock Split, Institutional Investor, Biotechnology